BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15654912)

  • 1. Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.
    Ando T; Yujiri T; Tominaga T; Shinya S; Takahashi T; Nomiyama J; Seguchi M; Matsubara A; Fujii Y; Tanizawa Y
    Eur J Haematol; 2005 Feb; 74(2):175-9. PubMed ID: 15654912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma.
    Toubai T; Hirate D; Shono Y; Ota S; Ibata M; Mashiko S; Sugita J; Shigematsu A; Miura Y; Kato N; Umehara S; Kahata K; Tsutsumi Y; Iwao N; Toyoshima N; Tanaka J; Asaka M; Imamura M
    Int J Lab Hematol; 2008 Feb; 30(1):75-81. PubMed ID: 18190473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
    Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
    Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
    [No Abstract]   [Full Text] [Related]  

  • 6. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma.
    Tapprich C; Fenk R; Schneider P; Bernhardt A; Haas R; Kobbe G
    Bone Marrow Transplant; 2003 Sep; 32(6):629-31. PubMed ID: 12953137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.
    Magro E; Regidor C; Cabrera R; Sanjuán I; Forès R; Garcia-Marco JA; Ruiz E; Gil S; Bautista G; Millán I; Madrigal A; Fernandez MN
    Haematologica; 2006 May; 91(5):640-8. PubMed ID: 16670070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
    Dodero A; Perfetti V; Ciceri F; Corradini P
    Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
    Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect.
    Takami A; Takamatsu H; Yamazaki H; Ishiyama K; Okumura H; Ohata K; Konaka H; Asakura H; Namiki M; Nakao S
    Bone Marrow Transplant; 2006 Dec; 38(11):729-32. PubMed ID: 17028623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of allogeneic stem cell transplantation in multiple myeloma.
    Bruno B; Giaccone L; Sorasio R; Boccadoro M
    Semin Hematol; 2009 Apr; 46(2):158-65. PubMed ID: 19389499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
    van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
    Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of unrelated transplants in patients with multiple myeloma.
    Ballen KK; King R; Carston M; Kollman C; Nelson G; Lim S; Reece D; Giralt S; Vesole DH
    Bone Marrow Transplant; 2005 Apr; 35(7):675-81. PubMed ID: 15723085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome.
    Boelens JJ; Rocha V; Aldenhoven M; Wynn R; O'Meara A; Michel G; Ionescu I; Parikh S; Prasad VK; Szabolcs P; Escolar M; Gluckman E; Cavazzana-Calvo M; Kurtzberg J;
    Biol Blood Marrow Transplant; 2009 May; 15(5):618-25. PubMed ID: 19361754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of allogeneic stem cell transplantation in multiple myeloma.
    Thomson KJ; Peggs KS
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):455-64. PubMed ID: 16001953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.